Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

Int J Infect Dis. 2005 Nov;9(6):317-22. doi: 10.1016/j.ijid.2004.09.012. Epub 2005 Sep 23.


Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002.

Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran.

Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated.

Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen.

Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amikacin / administration & dosage
  • Amikacin / therapeutic use
  • Antitubercular Agents / therapeutic use*
  • Cycloserine / administration & dosage
  • Cycloserine / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Iran
  • Isoniazid / administration & dosage
  • Isoniazid / therapeutic use
  • Male
  • Middle Aged
  • Ofloxacin / administration & dosage
  • Ofloxacin / therapeutic use
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology


  • Antitubercular Agents
  • Amikacin
  • Cycloserine
  • Ofloxacin
  • Isoniazid